APA
Modjarrad K., Lin L., George S. L., Stephenson K. E., Eckels K. H., De La Barrera R. A., Jarman R. G., Sondergaard E., Tennant J., Ansel J. L., Mills K., Koren M., Robb M. L., Barrett J., Thompson J., Kosel A. E., Dawson P., Hale A., Tan C. S., Walsh S. R., Meyer K. E., Brien J., Crowell T. A., Blazevic A., Mosby K., Larocca R. A., Abbink P., Boyd M., Bricault C. A., Seaman M. S., Basil A., Walsh M., Tonwe V., Hoft D. F., Thomas S. J., Barouch D. H. & Michael N. L. (20180418). Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. : Lancet (London, England).
Chicago
Modjarrad Kayvon, Lin Leyi, George Sarah L, Stephenson Kathryn E, Eckels Kenneth H, De La Barrera Rafael A, Jarman Richard G, Sondergaard Erica, Tennant Janice, Ansel Jessica L, Mills Kristin, Koren Michael, Robb Merlin L, Barrett Jill, Thompson Jason, Kosel Alison E, Dawson Peter, Hale Andrew, Tan C Sabrina, Walsh Stephen R, Meyer Keith E, Brien James, Crowell Trevor A, Blazevic Azra, Mosby Karla, Larocca Rafael A, Abbink Peter, Boyd Michael, Bricault Christine A, Seaman Michael S, Basil Anne, Walsh Melissa, Tonwe Veronica, Hoft Daniel F, Thomas Stephen J, Barouch Dan H and Michael Nelson L. 20180418. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. : Lancet (London, England).
Harvard
Modjarrad K., Lin L., George S. L., Stephenson K. E., Eckels K. H., De La Barrera R. A., Jarman R. G., Sondergaard E., Tennant J., Ansel J. L., Mills K., Koren M., Robb M. L., Barrett J., Thompson J., Kosel A. E., Dawson P., Hale A., Tan C. S., Walsh S. R., Meyer K. E., Brien J., Crowell T. A., Blazevic A., Mosby K., Larocca R. A., Abbink P., Boyd M., Bricault C. A., Seaman M. S., Basil A., Walsh M., Tonwe V., Hoft D. F., Thomas S. J., Barouch D. H. and Michael N. L. (20180418). Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. : Lancet (London, England).
MLA
Modjarrad Kayvon, Lin Leyi, George Sarah L, Stephenson Kathryn E, Eckels Kenneth H, De La Barrera Rafael A, Jarman Richard G, Sondergaard Erica, Tennant Janice, Ansel Jessica L, Mills Kristin, Koren Michael, Robb Merlin L, Barrett Jill, Thompson Jason, Kosel Alison E, Dawson Peter, Hale Andrew, Tan C Sabrina, Walsh Stephen R, Meyer Keith E, Brien James, Crowell Trevor A, Blazevic Azra, Mosby Karla, Larocca Rafael A, Abbink Peter, Boyd Michael, Bricault Christine A, Seaman Michael S, Basil Anne, Walsh Melissa, Tonwe Veronica, Hoft Daniel F, Thomas Stephen J, Barouch Dan H and Michael Nelson L. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. : Lancet (London, England). 20180418.